Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Phase 1/2 Recruiting 140 enrolled The Cooper Health System Society of Vascular and Interventional Neurology · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?

Timeline

Start: 2024-06-17
Primary completion: 2028-06
Completion: 2028-06

Publications

Background Khalife J, Tonetti DA, Shaikh H, Jovin T, Patel P, Thomas A. Intraarterial Bevacizumab Administration Through the Middle Meningeal Artery for Chronic Subdural Hematoma. Stroke Vasc Interv Neurol. 2023 Feb 25;3(4):e000722. doi: 10.1161/SVIN.122.000722. eCollection 2023 Jul.
Background Khalife J, Koneru M, Tonetti DA, Shaikh HA, Jovin TG, Patel PD, Thomas AJ. Intra-arterial Selective Bevacizumab Administration in the Middle Meningeal Artery for Chronic Subdural Hematoma: An Early Experience in 12 Hemispheres. Stroke Vasc Interv Neurol. 2024 Jul 22;4(5):e001409. doi: 10.1161/SVIN.124.001409. eCollection 2024 Sep.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	2 mg/kg	Other
Subject	Bevacizumab	Monoclonal antibody	4 mg/kg	Other

Indications

No indication recorded.